Welcome to the e-CCO Library!

DOP13 Clinical and endoscopic response to ustekinumab in Crohn’s disease: Week 16 interim analysis of the STARDUST trial
Year: 2020
Source:

ECCO'20 Vienna

Authors:

S. Danese1, S. Vermeire2, G. D’Haens3, J. Panés4, A. Dignass5, F. Magro6, M. Nazar7, M. Le Bars8, S. Sloan9, M. Lahaye10, L. Ni11, M. Daperno12, M. Lukáš13, A. Armuzzi14, M. Löwenberg3, D.R. Gaya15, L. Peyrin-Biroulet16

Created: Thursday, 30 January 2020, 10:12 AM
DOP13: Artificial Intelligence (AI) in endoscopy - Deep learning for detection and scoring of Ulcerative Colitis (UC) disease activity under multiple scoring systems
Year: 2021
Source: ECCO'21 Virtual
Authors: Byrne, M.(1);East, J.(2);Iacucci, M.(3);Panaccione, R.(4);Kalapala, R.(5);Duvvur, N.(5);Rughwani, H.(5);Singh, A.(5);Henkel, M.(6);Canaran, L.(7);Laage, G.(7);St-Denis, L.(7);Nikfal, S.(7);Asselin, J.(7);Monsurate, R.(8);Cremonese, E.(7);Soudan, F.(7);Travis, S.(9)
Created: Wednesday, 2 June 2021, 4:12 PM
DOP13: Clinical and endoscopic response to ustekinumab in Crohn’s Disease: Week 16 interim analysis of the STARDUST trial
Year: 2020
Source: ECCO'20 Vienna
Authors: Silvio Danese
Created: Tuesday, 23 June 2020, 5:40 PM
DOP13: Clinical and endoscopic response to ustekinumab in Crohn’s Disease: Week 16 interim analysis of the STARDUST trial
Year: 2020
Source: ECCO'20 Vienna
Authors: Silvio Danese
Created: Tuesday, 23 June 2020, 4:58 PM
Files: 1
DOP13: Immune profiling of adipose tissue in murine models of Inflammatory Bowel Disease (IBD)
Year: 2019
Source: ECCO'19 Copenhagen
Authors: Marilena Letizia
Created: Tuesday, 28 May 2019, 3:32 PM
Immunology
Files: 1
DOP13: Immune profiling of adipose tissue in murine models of inflammatory bowel disease (IBD)
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

M. Letizia*1, Y. Rodriguez Sillke1, F. Schmidt1, C. Günther2, D. Kunkel3, R. Glauben1, B. Siegmund1, C. Weidinger1

Created: Friday, 22 February 2019, 9:41 AM
DOP13: Plasma metabolite fingerprint could discriminate inflammatory bowel disease patients from healthy subjects
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Klaudia Farkas
Created: Friday, 14 July 2023, 2:22 PM
DOP13: Plasma metabolite fingerprint could discriminate inflammatory bowel disease patients from healthy subjects
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Farkas, K.(1)*;Endre, G.(2);Bacsur, P.(1);Resál, T.(1);Kocsmárszky-Koósz, V.(2);Tömösi, F.(2);Tóth, E.(2);Rutka, M.(1);Bálint, A.(1);Fábián, A.(1);Bor, R.(1);Szepes, Z.(1);Goretity, Á.(2);Thibodeau, I.(2);Molnár, T.(1);
Created: Friday, 14 July 2023, 10:43 AM
DOP13: The Arborisation index: An MRI-based measure of mesenteric hyperaemia in Crohn’s Disease
Year: 2022
Source: ECCO'22
Authors: Naim, I.(1,2);Darie, A.M.(1,2);Hoad, C.(2,3);Gowland, P.(2,3);Moran, G.W.(1,2);
Created: Friday, 11 February 2022, 3:52 PM
DOP14 Modelling of the relationship between infliximab exposure, faecal calprotectin, and endoscopic remission in patients with Crohn’s disease
Year: 2020
Source:

ECCO'20 Vienna

Authors:

E. Dreesen1, S. Berends2, D. Laharie3, G. D’Haens4, S. Vermeire5, A. Gils1, R. Mathôt2

Created: Thursday, 30 January 2020, 10:12 AM
DOP14: Identification and validation of a lipidomic signature as a novel diagnostic biomarker of paediatric Inflammatory Bowel Disease
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Niklas Nyström
Created: Friday, 14 July 2023, 2:22 PM
DOP14: Identification and validation of a lipidomic signature as a novel diagnostic biomarker of paediatric Inflammatory Bowel Disease
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Salihovic, S.(1);Nyström, N.(2)*;Bache-Wiig Mathisen, C.(3);Andersen, S.(4);Olbjørn, C.(5);Perminow, G.(6);Opheim, R.(7);Detlie, T.E.(8);Huppertz-Hauss, G.(9);Bazov, I.(1);Kruse, R.(10);Lindqvist, C.M.(1);Hedin, C.R.H.(11);Carlson, M.(12);Öhman, L.(13);Magnusson, M.(13);Keita, Å.V.(14);Söderholm, J.D.(14);D'Amato, M.(15);Orešič, M.(1);Repsilber, D.(1);Hyötyläinen, T.(16);Hoivik, M.L.(3);Halfvarson, J.(17);
Created: Friday, 14 July 2023, 10:43 AM
DOP14: TiO2 nanoparticles abrogate the protective effect of the autoimmunity-associated PTPN22R619W variant during acute DSS colitis
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

M. Schwarzfischer*1, L. Hering1, E. Katkeviciute1, A. Niechcial1, K. Atrott1, K. Bäbler1, P. Busenhart1, G. Rogler1, M. Scharl1, M. Spalinger1

Created: Friday, 22 February 2019, 9:41 AM
DOP14: Ultra-high magnification endocytoscopy and molecular markers for defining endoscopic and histologic remission in Ulcerative Colitis
Year: 2021
Source: ECCO'21 Virtual
Authors: Iacucci, M.(1,2,3);Nardone, O.M.(1);Jeffery, L.(1);Acharjee, A.(4);Zardo, D.(5);Smith, S.C.(1);Bazarova, A.(6);Cannatelli, R.(1);Shivaji, U.N.(1);Williams, J.(4);Georgios, G.(4);Ghosh, S.(1,2,3)
Created: Wednesday, 2 June 2021, 4:12 PM
DOP14: Validation of a new OPtical diagnosis Training platform to Improve dysplasia Characterisation in Inflammatory Bowel Disease (OPTIC-IBD): A multicentre randomised controlled study
Year: 2022
Source: ECCO'22
Authors: Iacucci , M.(1,2);Ingram , R.J.M.(1,2);Bazarova , A.(3);Cannatelli , R.(4);Labarile , N.(5);Nardone , O.M.(6);Parigi , T.L.(1,7);Siau , K.(8);Smith , S.C.L.(1);Ferraz , J.G.P.(2);Kiesslich , R.(9);Panaccione , R.(2);Parra-Blanco , A.(10);Tontini , G.E.(11,12);Uraoka , T.(13);Ghosh , S.(14);
Created: Friday, 11 February 2022, 3:52 PM
DOP15 Transmural healing with vedolizumab in patients with active Crohn’s disease
Year: 2020
Source:

ECCO'20 Vienna

Authors:

J. Rimola1, J.F. Colombel2, B. Bressler3, S. Adsul4, J. Siegelman5, P.E. Cole6, D. Lindner7, S. Danese8

Created: Thursday, 30 January 2020, 10:12 AM
DOP15: An evaluation of the exposure-efficacy relationship for subcutaneous vedolizumab maintenance treatment of Crohn’s Disease: Pharmacokinetic findings from VISIBLE 2
Year: 2020
Source: ECCO'20 Vienna
Authors: Shashi Adsul
Created: Tuesday, 23 June 2020, 5:40 PM
Last Modified: Thursday, 2 July 2020, 12:11 PM by Eloise Lanaud
DOP15: Clinical relevance of endoscopic peri-appendiceal red patch in Ulcerative Colitis patients
Year: 2021
Source: ECCO'21 Virtual
Authors: Reijntjes, M.(1);Heuthorst, L.(1);Gecse, K.(2);Mookhoek, A.(3);Bemelman, W.(1);Buskens, C.(1)
Created: Wednesday, 2 June 2021, 4:12 PM